History

NGeneBio started from the first in-house subcommittee system of Korea Telecom company and established to commercialize the technology accumulated through the establishment of a joint research institute with Seoul National University and various genome researches after the first cloud-based gene analysis project in Korea.

2019 Spread wings

03 1st in-house training with European distributor, BeDia Genomics France 
NGeneAnalySys updated version released
02 Attending MEDICA 2019 in Dubai, UAE
Partnerships with Types of Technology Est. in Saudi Arabia, PT. Luhur Wiratama in Indonesia, and Sure Bio Diagnostics & Pharmaceuticals in Pakistan
01 Partnership with BeDia Genomics in France

2018 Take off to the world

12 ISO 13485 2016 certificate received
11 HEMEaccuTest CE-IVD approved
Attending MEDICA2018 in Düsseldorf, Germany
10 Partnerships with BioMed Global Singapore and Ozgun Kimya A.S. Turkey
09 ISO 9001 certificate received
08 2nd oversea a demonstration of HEMEaccuTest and BRCAaccuTest PLUS in Singapore
ISO 13485 and ISO 9001 inspection
07 Attending FEME 2018 in Florida and AACC 2018 in Chicago, USA
05 1st oversea demonstration of BRCAaccuTest PLUS in Italy
Partnership with AmitisGen Med TECH Group, Iran
02 Attending  MEDLAB 2018 in Dubai, UAE

2017 Technology commercialization

07 Institutional review board registered  for in vitro diagnostic reagent
06 BRCAaccuTestTM  & NGeneAnalySysTM CE-IVD approved
05 ISO13485 certificated NGS software
04 Korean Ministry of Food and Drug Safety approved clinical trail for NGS panel
02 GMP certification for NGS software and in vitro diagnosis medical device & quality criterion
01 Released NGeneAnalySys

2016 Commercialization foundation

12 Acquired ISO 9001, 13485 Certification
11 Contracted development and development of chemotherapy drug development project
10 Acquired GMP certification for in vitro diagnostic reagent
08 Selected for Intellectual Property R&D
07 Genetic Testing Agency Approved
06 Launched NGS based breast cancer panel & S/W (illumina MiSeq & MiSeq Dx), Selected as a project to commercialize fetal genetic diseases
05 Selected as an NGS disease analysis platform commercialization project
03 Designated as a venture enterprise

2015 Established NGeneBio

12 Built NGS Molecular Laboratory
11 Selected NGS based chemotherapy diagnosis project, the establishment of a company-affiliated research institute
10 Established NGeneBio Co., Ltd.

2014

15.10 Established NGeneBio and Spin off
12 Launched cloud-based genome service, established Korea Telecom company (CIC) No. 1